• Regulatory NewsRegulatory News

    Brexit, medicine availability top EMA stakeholder report

    Brexit readiness, regulatory science strategic planning, and medicine availability topped the list of big-picture areas of engagement between the European Medicines Agency (EMA) and industry stakeholders in a newly released biennial report.   The EMA report , released Friday and covering the 2018-19 biennium, was presented to EMA’s Management Board in December 2020. It provides a high-level look at interaction between the European regulator and the pharmaceutical indu...
  • ReconRecon

    Recon: Record-shattering 2020 healthcare investment; BIO layoffs

    Welcome to Regulatory Reconnaissance, your daily regulatory news and intelligence briefing.   In Focus: US Who’s who in Biden’s health care team ( Medical Economics ) Biden begins presidency with aggressive healthcare agenda ( Healthcare IT News ) Biden Inherits a Vaccine Supply Unlikely to Grow Before April ( NYT ) Biden administration is trying to figure out what’s delaying Covid vaccine shots, CDC says ( CNBC ) How To Fix The Covid-19 Vaccine Rollout ( Forbes )...
  • Regulatory NewsRegulatory News

    Amid pandemic, EMA's 2020 authorizations ticked upward

    Despite the pandemic, the European Medicines Agency (EMA) issued many more positive recommendations for human medicines in 2020 than in the previous year, according to a new report from the agency highlighting the year’s regulatory activities.   In 2020, 97 new medicines were recommended for authorization by EMA; of these, 39 contain a new active substance (NAS). In 2019, EMA issued 66 positive opinions for medicines, 30 of which contained a NAS. The total numbers of n...
  • Regulatory NewsRegulatory News

    FDA sped progress for most of 2020's novel drugs

    Most novel drugs approved by the US Food and Drug Administration (FDA) in 2020 made their way through the approvals process using one or more expedited approval pathways, and over half of sponsors received the incentives that accompany orphan drug designation, according to an FDA report detailing the year’s approvals.   Novel drug approvals continued at a brisk clip, averaging over one per week in 2020. Despite the pandemic the 53 novel drugs approved in 2020 bested 20...
  • Regulatory NewsRegulatory News

    In 2020, all goal dates met for CDER's novel approvals

        Editor’s note: come back to Regulatory Focus tomorrow for an expanded examination of these approvals, including which sponsors made use of expedited programs, and which programs were used most frequently.   A slate of 53 drugs makes up the list of novel drugs approved by the US Food and Drug Administration in 2020. The list, released Wednesday, includes such notables as Veklury (remdesivir, Gilead), a shelved antiviral repurposed to treat COVID-19 infection,...
  • Industry, FDA begin to hammer out PDUFA VII details

    Discussions continue between industry and the US Food and Drug Administration (FDA) regarding the upcoming reauthorization of user fees for prescription drugs, biologics and generic drugs. After public hearing and a first round of meetings that gave a peek into priorities for industry and regulator representatives, this next round began to sort out some detail. (RELATED: PDUFA VII: FDA and industry set priorities in first round of negotiations , Regulatory Focus 29 Octo...
  • Regulatory NewsRegulatory News

    FDA: 2 years until SPL E-submission for REMS docs

    The US Food and Drug Administration (FDA) has issued final guidance on the electronic submission of documents related to the Risk Evaluation and Mitigation Strategies (REMS) using the Structured Product Labeling (SPL) format. The final guidance document starts the clock on compliance, with the new formatting requirements taking effect on 28 December 2022.   In the final guidance document, the FDA outlines how it will implement the requirements for e-submission of REM...
  • Regulatory NewsRegulatory News

    FDA releases draft guidance on dry eye therapies

    A new draft guidance from the US Food and Drug Administration (FDA) addresses considerations for developing drugs to treat dry eye. The guidance encompasses development of both pharmaceutical and biological products to address the common eye condition.   The best trial design, said FDA, is a per-patient randomized, double-masked trial that looks for superiority of an investigational product over the control, which could be the vehicle. Either a traditional environmenta...
  • Regulatory NewsRegulatory News

    FDA's proprietary name guidance seeks to avoid medication errors

    The US Food and Drug Administration (FDA) has issued a pair of draft guidance documents aimed at guiding the selection of proprietary names for prescription and non-prescription drugs.   The best practices set forth in the guidances are designed “to help minimize proprietary name-related medication errors and otherwise avoid adoption of proprietary names that contribute to violations of the Federal Food, Drug, and Cosmetic Act (FD&C Act) and its implementing regulation...
  • Regulatory NewsRegulatory News

    EU regulators set network strategy to 2025

    The European Medicines Agency (EMA) and the Heads of Medicines Agencies (HMA) have adopted their next five-year network strategy following its adoption by the EMA’s management board and HMA.   The 53-page strategy, which was released for consultation in July, focuses on six priority areas for the network of regulators:   availability and accessibility of medicines; data analytics, digital tools and digital transformation; innovation; antimicrobial resistance an...
  • Regulatory NewsRegulatory News

    From FDA: How to conduct DDI studies with acid-reducing drugs

    A new draft guidance from the US Food and Drug Administration (FDA) addresses how to conduct drug-drug interaction studies with acid-reducing medicines that can make the gastric environment more alkaline.    Medicines such as proton pump inhibitors and histamine H2 receptor antagonists, dubbed acid-reducing agents or ARAs, are in wide use and many are available without a prescription. “ARAs can affect the solubility and dissolution characteristics of orally administere...
  • Regulatory NewsRegulatory News

    FDA launches online orphan submissions portal

    The US Food and Drug Administration (FDA) on Monday launched a new cloud-based submission portal for orphan drug designation requests, shifting away from the current paper and CD-based submission process. The new portal, first announced in January, is part of the agency’s orphan drug technology modernization effort and fits in with its broader technology modernization plans. The shift to electronic submissions follows a decade of increasing orphan drug designation reques...